Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences (NASDAQ: SSKN) announced COFEPRIS clearance of its TheraClearX® acne treatment system under Device Registration No. 3187E2024SSA, valid through November 2029, authorizing importation, commercialization, and clinical use across Mexico.

STRATA initiated commercial rollout with partner MINO Labs, placing the first system with Dr. Melissa Lomelí Canedo in Mexico City. The company will offer TheraClearX® via its usage-based physician partnership model and plans expanded deployments, clinician training, real-world data collection, and further Latin America registrations in 2026.

Market context cited: professional acne medication segment CAGR ~10.2% to 2030, average session ~MXN 3,200 (≈USD 174), and approximately 3,000 licensed dermatologists in Mexico.

STRATA Skin Sciences (NASDAQ: SSKN) said a U.S. District Court partially granted a preliminary injunction on Nov 8, 2024, barring LaserOptek and related parties from U.S. sales/marketing that imply reimbursement under CPT codes 96920–96922 and from making false or misleading statements about STRATA products. The Court also added LaserOptek Korea as a defendant for obscuring involvement. STRATA reports >20 former Pallas buyers have switched to XTRAC, representing $1M+ in annualized capital and recurring revenue. As of June 30, 2025, STRATA’s partnership program covers 844 of ~1,200 U.S. excimer-using clinics. The AMA CPT Board reaffirmed exclusive excimer use under these codes through Jan 1, 2027, with codes broadened in May 2025 to include up to 30 conditions, potentially expanding treated patient population.

STRATA Skin Sciences (NASDAQ: SSKN) highlighted a first English-language case study (Case Rep Oncol 2025;18:325–329) reporting successful use of the 308-nm excimer (XTRAC) laser to treat poikilodermatous mycosis fungoides (pMF), a rare cutaneous T‑cell lymphoma subtype. A 50-year-old patient received 1,250 mJ/cm² over five sessions with topical corticosteroids and showed marked improvement with near-complete lesion resolution at three months. The release cites a 2023 systematic review (14 studies, 72 patients) reporting 73.6% complete clinical response and low relapse (5.7% at mean 13 months) for 308-nm excimer therapy, arguing for a targeted alternative to whole-body phototherapies and noting ongoing reimbursement engagement with CMS.

STRATA Skin Sciences (NASDAQ: SSKN) on Oct 3, 2025 highlighted peer‑reviewed evidence validating its XTRAC® 308 nm Excimer Laser as a safe, effective therapy for localized atopic dermatitis.

The release notes the AMA has expanded excimer laser indications to inflammatory and autoimmune skin diseases, enabling Medicare, Medicaid and private payer reimbursement for atopic dermatitis. The PR cites clinical results: 81% itch reduction (Baltás et al.), randomized trial equivalence/superiority vs. clobetasol with longer durability (Brenninkmeijer et al.), and in refractory hand/foot eczema 69% severity reduction, 70% symptom score reduction, 87% clear/almost clear, and average remission of 11.3 months (Shroff et al.). The company emphasizes targeted, steroid‑sparing treatment benefits and reduced UV exposure versus whole‑body phototherapy.

STRATA Skin Sciences (NASDAQ: SSKN) has announced positive results from a new peer-reviewed study published in Lasers in Medical Science, demonstrating the enhanced efficacy of its XTRAC® 308nm Excimer Laser when combined with tacrolimus ointment for treating plaque-type psoriasis.

The study of 100 patients showed that the combination therapy group achieved superior results compared to topical treatment alone. The combination therapy group's mean PASI score decreased from 18.36 to 3.30, significantly outperforming the control group's reduction from 18.62 to 5.23 (p < 0.01). The treatment demonstrated a strong safety profile with no serious adverse events.

This research validates STRATA's personalized medicine approach, potentially strengthening their case for expanded CMS reimbursement and positioning their XTRAC system as a viable non-biologic treatment option.

STRATA Skin Sciences (NASDAQ: SSKN) has announced significant findings from a 251-patient randomized controlled study combining their 308nm Excimer laser with JAK inhibitors for vitiligo treatment. The study, published in the International Journal of Dermatology, demonstrated superior efficacy with 14.20% higher repigmentation compared to monotherapy.

Key results include 100% significant efficacy rate after 52 weeks of treatment, 96.5% pigmentation stability, and a low 8.8% relapse rate at one-year follow-up. The combination therapy showed excellent safety with no serious adverse events. This research supports STRATA's pursuit of expanded reimbursement for various indications, with the company targeting implementation by early 2026.

STRATA Skin Sciences (NASDAQ:SSKN), a medical technology company focused on dermatologic treatments, has completed its previously announced registered direct offering. The company successfully issued 1,097,547 shares of common stock at $2.204 per share, raising gross proceeds of approximately $2.42 million.

The offering, which closed on September 4, 2025, was conducted through Ladenburg Thalmann & Co. Inc. as the exclusive placement agent. STRATA plans to utilize the net proceeds for working capital and general corporate purposes. The securities were offered under an effective S-3 shelf registration statement.

STRATA Skin Sciences (NASDAQ: SSKN) reports significant success with its Elevate 360 (E360) consulting services platform, which helps partner clinics optimize their XTRAC laser treatment operations. The program focuses on implementing best practices in marketing, reimbursement, and patient retention.

Since early 2025, 99 out of 844 clinics have adopted E360, achieving an average 7% year-over-year growth. A notable case study showed one partner's revenue contribution to STRATA increasing from $10,500 in H1 2024 to $61,800 in H1 2025, while expanding from 2 to 9 clinics after implementing E360.

The program helps clinics optimize patient referrals, insurance reimbursement, scheduling, and follow-up visits, particularly beneficial with recent reimbursement improvements for vitiligo and auto-immune skin conditions.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced a $2.42 million registered direct offering of common stock. The company will sell 1,097,547 shares at $2.204 per share, priced at-market under Nasdaq rules.

The offering, expected to close around September 4, 2025, is being conducted with institutional investors, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. STRATA plans to use the proceeds for working capital and general corporate purposes. The offering is being made through a shelf registration statement previously declared effective by the SEC.